Various studies have estimated that these anticompetitive agreements cost American consumers between $3 billion and $12 billion every year. The Federal Trade Commission and consumer-rights organizations that have fought Big Pharma on this issue since 1999 are to be congratulated,? said Steve Shadowen of the Austin- based law firm Hilliar
The Supreme Court ruled Monday that brand-name drugmakers can be sued for violating antitrust laws if they make a deal that pays a potential competitor to put off selling a generic version. The 5-3 decision is likely to benefit consumers with lower prices. The Federal Trade Commission, which has pursued lawsuits against the drugmakers, estimated th
Elan's financial advisers contacted Royalty Pharma's financial advisers over the weekend of 15/ 16 June for the purpose of inviting Royalty Pharma to participate in that process. *Royalty Pharma had sought the approval from the Irish Takeover Panel to allow it to amend its offer so it would not lapse should the Share Repurchase Program or the ELND0
Research and Markets has announced the addition of the "Injectable Drug Delivery Market by Formulations, Devices& Therapeutics- Global Forecasts to 2017" report to their offering. The global injectable drug delivery technologies market was valued at $22.5 billion in 2012, and is expected to reach $43.3 billion by 2017 at a CAGR of 14.0% from 2012 t
NESS ZIONA, Israel, June 18, 2013/ PRNewswire/. Mapi Pharma Ltd., developer of complex bulk Active Pharmaceutical Ingredients, generic and innovative intermediates, and finished dosage forms based on selected drug delivery systems, announced today that the company has been granted a United States patent for Tapentadol. Tapentadol is indicated in
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, over the past 12 months, 25 percent of surveyed physicians from the EU5 have been required to change the antiretroviral prescription for some or most of their HIV patients, primarily to reduce costs. The new European Phys
The American Antitrust Institute issued the following news release:. The American Antitrust Institute gives two-and-a-half cheers for the Supreme Court's decision, which supports application of the antitrust laws to reverse payment settlements in which branded drug companies holding patents pay allegedly infringing generic drug firms to stay out of
The AARP issued the following news release:. Today, AARP Senior Vice President, Government Affairs, Joyce Rogers, offered the following statement in reaction to the Supreme Court's decision in the pay-for-delay prescription drug case. "AARP is pleased with the Supreme Court decision in the pay-for-delay prescription drug case, Federal Trade Commis
Actavis' ANDA product is a generic version of Fresenius Kabi's Diprivan, which is an intravenously administered sedative and anesthetic. Fresenius Kabi USA, LLC filed suit against Actavis on June 6, 2013, in the U.S. District Court for the District of Delaware seeking to prevent Actavis from commercializing its ANDA product prior to the expiration
Statement attributable to: Jeremy A. Lazarus, M.D., President, American Medical Association "The American Medical Association applauds the U.S. Supreme Court ruling today confirming that the Federal Trade Commission has the authority to challenge anti-competitive market barriers that deny patients access to affordable generic medications. There mus
The lives of thousands of Ugandans enrolled on HIV treatment hang in the balance after an application by poor countries to extend the deadline for manufacture of generic AIDS drugs was rejected by the World Trade Organization under a treaty known as Trade Related Aspects of Intellectual Property. Over 90% of HIV drugs in Uganda are generic drugs...
Actavis, the U.S. Supreme Court ruled that the Federal Trade Commission case against the payoff keeping generic AndroGel from the market can move ahead in the lower courts. The court chose not to declare all such payoffs unlawful, however, spurring consumer advocates to call on Congress to finish the job. And while we're disappointed the court did
Subsequently, Actavis and Paddock filed applications for generic drugs modeled after AndroGel and certified under the federal law that Solvay's patent was invalid and that their drugs did not infringe it. Solvay sued Actavis and Paddock, claiming patent infringement. But the FDA eventually approved Actavis' generic product.
WASHINGTON Deals between pharmaceutical corporations and their generic drug competitors, which government officials say keep cheaper forms of medicine off the market, can sometimes be illegal and therefore can be challenged in court, the Supreme Court said Monday. But "this court's precedents make clear that patent-related settlement agreements
*Royalty Pharma had sought the approval from the Irish Takeover Panel to allow it to amend its offer so it would not lapse should the Share Repurchase Program or the ELND005 Transaction be approved by shareholders at the EGM. Royalty Pharma has launched judicial review proceedings in the Irish High Court against the decision of the Irish Takeover P
By a News Reporter-Staff News Editor at Pharma Business Week FUJIFILM Corporation and Dr. Reddy's Laboratories Ltd. have decided to terminate the Memorandum of Understanding to enter into an exclusive partnership in the generic drugs business for the Japanese market and to establish a joint venture in Japan. Commenting on the development, GV Pras
Glenmark deployed the Revitas CARS solution for chargeback and rebate management, as well as the Advanced Membership module for validations of contract and membership eligibility, in order to support the growth of its U.S. operations and keep pace with the increasingly competitive generic pharmaceutical market. "Revitas has been a trusted partner
By a News Reporter-Staff News Editor at Clinical Trials Week Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, announced results from a post-marketing study of the company's European biosimilar epoetin, Retacrit?. Full results of the study, called ORHEO, were presented at the 48 Annual Meeting of the Ame
Ranbaxy Labs has also been filing several applications to unveil generic versions of top-selling medicines from its local plant. Production of its generic version of the cholesterol-lowering medicine Lipitor Atorvastatin from US to its Mohali unit. India% s pharmaceutical giant Ranbaxy Laboratories Ltd aims to expand its manufacturing unit at M
Senators Amy Klobuchar and Chuck Grassley today issued the following statements regarding today's decision by the U.S. Supreme Court in FTC v. Activas, Inc. which held that pay-for-delay agreements between brand and generic drug companies are subject to antitrust scrutiny. Klobuchar, the chair of the Judiciary Antitrust Subcommittee, and Grassley,
In a release on June 12, the Company noted details of its service:. Many retailers, such as Walmart and Target, offer steep discounts on certain generic drugs. Prescriptions for some of the most common generic drugs only cost $4 on these programs.
Mylan Inc., a generic and specialty pharmaceutical company, has announced that Executive Chairman Robert Coury and CFO John Sheehan presented at the Goldman Sachs 34th Annual Global Healthcare Conference on June 12 at the Terranea Resort, Rancho Palos Verdes, California. An archived version of the conference will be available after the live present
The tools utilized by Medicare Part D plansincluding preferred pharmacy networks and generic alternativesare delivering savings, the Pharmaceutical Care Management Association said. "PBMs promote generics, create affordable pharmacy networks, and use other tools to reduce costs in Medicare Part D," said PCMA President and CEO Mark Merritt.
The Pharmaceutical Research and Manufacturers of America issued the following news release:. Pharmaceutical Research and Manufacturers of America Executive Vice President and General Counsel Mit Spears issued the following statement on the decision issued today by the U.S. Supreme Court in the case of Federal Trade Commission v. "We are pleased th
WASHINGTON, DC Today, Energy and Commerce Committee Ranking Member Henry A. Waxman issued the following statement on the decision by the Supreme Court in the case Federal Trade Commission v. Actavis allowing federal regulators to sue brand-name drug makers regarding anti-competitive practices to keep generic drugs off the market:. "Today, the Co
